Overview

TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study

Status:
Recruiting

Trial end date:
2024-08-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with pd-1 antibody immunotherapy (Sintilimab) and anti-VEGF (Bevacizumab Biosimilar) in patients with advanced hepatocellular carcinoma (BCLC-C Stage).

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Bevacizumab